Not every assay needs the same substrate. But every assay needs the right one.

In recent years, the country has promulgated centralized bulk-buying policy for high value medical consumables in the field of medical devices.

On August 26, Dian Diagnostics achieved operating income of CNY 10.753 billion, an increase of 85.68% over the same period last year; net profit attributable to the parent was CNY 1.880 billion, an increase of 158.54% over the same period last year.

Canadian firm Genomadix has entered into a collaboration with the Mayo Clinic to advance its point-of-care molecular analyzer technology.

Chinese sequencing tech company MGI Tech, a BGI affiliate, plans to go public this week in an initial public offering in China, targeting proceeds of CNY 2.53 billion (approximately $366.4 million based on Monday's exchange rate).

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. obtained the CE extension certificate issued by TüV SüD, a famous EU notified body under the IVDR regulations.

A new UC San Francisco study sheds light on the diversity within the most common type of pediatric liver tumor and suggests a way forward for more precise chemotherapy treatment.

Myriad Genetics said Friday that Japan's Ministry of Health, Labor, and Welfare has granted expanded coverage for the firm's BRACAnalysis test as a companion diagnostic to identify patients with early-stage

German firm Oncgnostics said on Thursday that China's National Medical Products Administration approved its DNA methylation-based cervical cancer GynTect assay.

Norwegian life sciences company Age Labs on Wednesday announced a partnership with Bay Area biotech BioAge Labs to harness data from a longitudinal Norwegian health study to develop new diagnostics and drugs.

In the first half of 2022, among the four major business lines of the company, the infectious disease business income reached 3.207 billion CNY, a significant increase of 240.32% over the same period of last year.

Roche said on Wednesday that its Ventana PD-L1 test has received a CE label expansion for its Ventana PD-L1 SP263 test to determine non-small cell lung cancer patients' eligibility for Roche's immune checkpoint inhibitor Tecentriq (atezolizumab).